The "inverted cup" - A novel in vitro release technique for drugs in lipid formulations

Journal of Controlled Release

Volumn 113, Issue 1, 2006, Pages 80-88

  Söderberg, Lars ^a,b   Dyhre, Henrik ^b   Roth, Bodil ^a   Björkman, Sven ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

In vitro release; In vitro in vivo correlation; Local anaesthetics; Parenteral depot formulations; Sciatic nerve block

Indexed keywords

BIOMEDICAL ENGINEERING; DRUG PRODUCTS; PHARMACOKINETICS; PHASE TRANSITIONS; VISCOSITY;

IN VITRO RELEASE; IN VITRO/IN VIVO CORRELATION; PARENTERAL DEPOT FORMULATIONS; POLAR LIPID FORMULATIONS; SCIATIC NERVE BLOCK;

LIPIDS;

BUPIVACAINE; LIDOCAINE; PRILOCAINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; EVALUATION; IN VITRO STUDY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; POLARIZATION; PRIORITY JOURNAL; RAT; VISCOSITY;

ANESTHETICS, LOCAL; ANIMALS; BUPIVACAINE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; LIDOCAINE; LIPIDS; MALE; NERVE BLOCK; PRILOCAINE; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE;

EID: 33744529011     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.03.015     Document Type: Article

References (35)

1. Radd B.L., Newman A.C., Fegely B.J., Chrzanowski F.A., Lichten J.L., and Walkling W.D. Development of haloperidol in oil injection formulations. J. Parenter. Sci. Technol. 39 1 (1985) 48-50
2. Jann M.W., Ereshefsky L., and Saklad S.R. Clinical pharmacokinetics of the depot antipsychotics. Clin. Pharmacokinet. 10 4 (1985) 315-333
3. Deanesly R., and Parkes A.S. Note on the subcutaneous absorption of oils by rats and mice, with special reference to the assay of oestrin. J. Physiol. 78 (1933) 155-160
4. Smitz J., Devroey P., Faguer B., Bourgain C., Camus M., and Van Steirteghem A.C. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod. 7 (1992) 168-175
5. Nieschlag E., Buchter D., Von Eckardstein S., Abshagen K., Simoni M., and Behre H.M. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol. 51 (1999) 757-763
6. Li Q.-G., Peggins O.J., Fleckenstein L.L., Masonic K., Heiffer M.H., and Brewer T.G. The pharmacokinetics and bioavailability of dihydroartemisin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 50 (1998) 173-182
7. Dyhre H., Wallin R., Björkman S., Engström S., and Renck H. Inclusion of lignocaine base into a polar lipid formulation - in vitro release, duration of peripheral nerve block and arterial blood concentrations in the rat. Acta Anaesthesiol. Scand. 45 (2001) 583-589
8. Söderberg L., Dyhre H., Roth B., and Björkman S. In-vitro release of bupivacaine from injectable lipid formulations investigated by a single drop technique-relation to duration of action in-vivo. J. Pharm. Pharmacol. 54 (2002) 747-755
9. Larsen D.B., Joergensen S., Olsen N.V., Hansen S.H., and Larsen C. In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. J. Control. Release 81 (2002) 145-154
10. Söderberg L., Dyhre H., Roth B., and Björkman S. Ultralong peripheral nerve block by lidocaine:prilocaine 1:1 mixture in a lipid depot formulation: comparison of in vitro, in vivo and effect kinetics. Anesthesiology 104 (2006) 110-121
11. Engström S. Drug delivery from cubic and other lipid-water phases. Lipid Technol. 2 (1990) 42-45
12. Engström S., and Engström L. Phase behaviour of the lignocaine-monoolein-water system. Int. J. Pharm. 79 (1992) 113-122
13. Engström S., Lindahl L., Wallin R., and Engblom J. A study of polar lipid drug carrier systems undergoing a thermoreversible lamellar-to-cubic phase transition. Int. J. Pharm. 86 (1992) 137-145
14. Norling T., Lading P., Engström S., Larsson K., Krog N., and Nissen S.S. Formulation of a drug delivery system based on a mixture of monoglycerides and triglycerides for use in the treatment of periodontal disease. J. Clin. Periodontol. 19 (1992) 687-692
15. Oradd G., Lindblom G., Fontell K., and Ljusberg-Wahren H. Phase diagram of soybean phosphatidylcholine-diacylglycerol-water studied by x-ray diffraction and 31P- and pulsed field gradient 1H-NMR: evidence for reversed micelles in the cubic phase. Biophys. J. 68 (1995) 1856-1863
16. Alfons K., and Engstrom S. Drug compatibility with the sponge phases formed in monoolein, water, and propylene glycol or poly(ethylene glycol). J. Pharm. Sci. 87 12 (1998) 1527-1530
17. Kuzma P.J., Kline M.D., Calkins M.D., and Staats P.S. Progress in the development of ultra-long-acting local anesthetics. Reg. Anesth. 22 (1997) 543-551
18. D'Souza S.S., and DeLuca P.P. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm. Res. 23 3 (2006) 460-474
19. FDA. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In vitro/In vivo Correlations (1997)
20. Uppoor V.R.S. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Release 73 (2001) 127-132
21. European Pharmacopoeia Ed. 4, supplement 4.8, Council of Europe, EDQM, 2004, p. 189-199, 3245-3250, 3895-3901.
22. USP 28, United States Pharmacopoeial Convention, Inc., Rockville, MD, p. 2412-2414.
23. Gido C., Langguth P., Kreuter J., Winter G., Woog H., and Mutschler E. Conventional versus novel conditions for the in vitro dissolution testing of parenteral slow release formulations: application to doxepin parenteral dosage forms. Pharmazie 48 (1993) 764-769
24. Gido C., Langguth P., and Mutschler E. Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles in dogs. Pharm. Res. 11 6 (1994) 800-808
25. Schultz K., Mollgaard B., Frokjaer S., and Larsen C. Rotating dialysis cell as in vitro release method for oily parenteral depot solutions. Int. J. Pharm. 157 (1997) 163-169
26. Larsen D.H., Fredholt K., and Larsen C. Assessment of rate of drug release from oil vehicle using a rotating dialysis cell. Eur. J. Pharm. Sci. 11 (2000) 223-229
27. Fredholt K., Larsen D.H., and Larsen C. Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur. J. Pharm. Sci. 11 (2000) 231-237
28. Larsen D.B., Fredholt K., and Larsen C. Addition of hydrogen bond donating excipients to oil solution: effect on in vitro drug release rate and viscosity. Eur. J. Pharm. Sci. 13 (2001) 403-410
29. Larsen D.B., Parshad H., Fredholt K., and Larsen C. Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. Int. J. Pharm. 232 (2002) 107-117
30. Parshad H., Frydenvang K., Liljefors T., and Cornett C. Assessment of drug salt release from solutions, suspensions and in situ suspensions using a rotating dialysis cell. Eur. J. Pharm. Sci. 19 (2003) 263-272
31. Pedersen B.T., Ostergaard J., Larsen S.W., and Larsen C. Characterization of the rotating dialysis cell as an in vitro model potentially useful for simulation of the pharmacokinetic fate of intra-articularly administered drugs. Eur. J. Pharm. Sci. 25 (2005) 73-79
32. Levy G. Effect of dosage form on drug absorption a frequent variable in clinical pharmacology. Arch. Int. Pharmacodyn. Ther. 152 (1964) 59-68
33. Brockmeier D., and von Hattingberg H.M. In vitro-in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. Arzneimittelforschung 32 (1982) 248-251
34. Ronald A., and Veng-Pedersen P. A note regarding curve fitting with a sum of exponentials. Biopharm. Drug Dispos. 9 (1988) 579-586
35. Brugerolle B., Attolini L., Roucoules X., and Lorec A.M. Cigarette smoke increases bupivacaine metabolism in rats. Can. J. Anaesth. 41 8 (1994) 733-737